

# The Latest Effective and Safe Alternative for Facial Skin Rejuvenation: RecoSMA®

*Groundbreaking study results: new method for skin rejuvenation proven by investigators at French University Hospital*

LONDON, UNITED KINGDOM, August 26, 2016 /EINPresswire.com/ -- [RecoSMA®](#) is a new non-invasive laser technology and procedure for tissue regeneration with a wide range of applications in aesthetic medicine that has been proven effective in a number of pre-clinical and clinical studies.

The aim of a recent study published in "Lasers in Surgery and Medicine"(1), was to objectively and subjectively assess the clinical efficacy and safety of [Erbium: YAG laser](#) combined with the SMA module, developed and patented by LINLINE, for [facial skin rejuvenation](#). The research was carried out by Dr Barbara Hersant, Dr Mounia Sid Ahmed-Mezi, Adrien Chossat, and Professor Jean-Paul Meningaud Head of the Department of Plastic and Cosmetic Reconstructive Surgery and Maxillo-facial Surgery at the Henri Mondor Hospital, Paris. Patients were treated using the Multiline™ laser platform. An Er:YAG laser combined with the SMA module fixed on the emitter was used.



“

It is a fascinating technology, which I think we should offer to all our patients...”

*Professor Jean-Paul Meningaud*

This SMA module when adapted to the Er:YAG emitter has a sophisticated system of lenses that perforate 50 µm holes in the skin. The technology combines the erbium-doped yttrium aluminum garnet (Er:YAG) laser, which operates at a wavelength of 2,940 nm and a specific SMA nozzle. The laser beam is fractionated into thousands of microbeams (about 10,000/cm<sup>2</sup>) of 50 µm in diameter, spaced by 50 µm. Hernandez(2) has recently used Er:YAG

laser combined with SMA for the treatment of chronic lower extremity ulcers, and they have shown that this new technology is safe, effective and may be used as a therapeutic alternative in the treatment of chronic wounds.

Method: Patients with Fitzpatrick skin type's I-IV were prospectively included. Inclusion criteria consisted of having wrinkles and irregular skin texture. All patients underwent two Er:YAG + SMA sessions (1 month apart) to stimulate tissue regeneration. Aesthetic improvement was

qualitatively assessed using digital photographs. Side effects were investigated after each session. Thirty-four patients were included, 50% (18 patients) had Fitzpatrick skin type III and 41% (14 patients) were smokers.

Results: Skin firmness and elasticity change over time, facial skin in particular. This leads to facial sagging (firmness and elasticity loss) and the appearance of wrinkles and fine lines. After treatment skin elasticity indices were significantly improved. No adverse reactions were reported.

Conclusion: The Er:YAG + SMA technology offers an effective and safe treatment alternative for facial skin rejuvenation. It reduces the recovery time compared to conventional lasers such as carbon dioxide lasers. The 2,940 nm Er:YAG laser combined with the SMA module clinically improves facial appearance, reduces ageing signs and induces biomechanical effects associated with improved skin firmness and elasticity.

Professor Meningaud commented "Skin elasticity increased by an average 14-19% in all patients, who visually looked 4-5 years younger. It is a fascinating technology, which I think we should offer to all our patients..."

LINLINE (<http://www.linline.com>) is an international manufacturer of high quality medical laser devices for aesthetic, dermatological and surgical purposes.

SOURCE LINLINE Medical Systems SAS

1. Published online in Wiley Online Library ([wileyonlinelibrary.com](http://wileyonlinelibrary.com)). DOI 10.1002/lsm.22561

2. Hernández, E; Vascular Surgeon, Vascular Surgery Service, Viamed Monegal Hospital, Tarragona, Spain.

Richie Hunt  
LINLINE Medical Systems  
+44(0)774-RECOSMA  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.